Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Plasma leptin tied to sleep quality in obese T2DM patients

13 Mar 2018

In obese patients with type 2 diabetes mellitus (T2DM), higher plasma levels of leptin appear to be associated with better sleep quality, a recent study has shown.

Researchers performed a cross-sectional study of 182 T2DM patients, of whom 113 had body mass index (BMI) ≥25 kg/m2 and were identified as obese. Single-channel electroencephalography was used to assess sleep architecture, while enzyme-linked immunosorbent assays were performed to measure fasting plasma leptin concentrations.

The median plasma leptin concentration in the study cohort was 6.6 ng/mL. In the obesity group, the median concentration was 9.9 ng/L, which was significantly higher than the 3.6 ng/mL in the nonobesity group. The median apnoea-hypopnoea index (AHI) value in the obesity group was likewise significantly higher than in the nonobesity group (13.9/hour vs 5.8/hour).

In multiple regression analysis, leptin levels were positively associated with delta power in the entire cohort (β, 0.226; p=0.075) with borderline significance. Age (β, –0.490; p<0.01) and BMI (β, –0.238; p<0.05) were also significantly associated with delta power. The models were adjusted for age, BMI, sex, blood pressure, AHI and leptin levels.

When analyses were restricted to either obese or nonobese participants, researchers found that leptin levels had a significant, strong and positive correlation with delta power among obese (β, 0.399; p<0.01) but not nonobese T2DM patients.

“The present study demonstrated that plasma leptin level was positively associated with delta power during the first sleep cycle, an established marker for sleep quality, only in obese T2DM patients, but not in nonobese counterparts,” noted researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.